Phase 1 open-label dose escalation study with no results posted; designed to explore safety and feasibility in a small uncontrolled cohort.
Reported
Planned enrollment11
Study phasePHASE 1
Primary outcome: Peak VO2Measured at screening, month 6, 9 and month…